GL Pharmtech Q1 2026 Revenue Up 20%... Dry Eye Drug GLH8NDE Submitted for Approval

Consolidated revenue for Q1 2026: 9,433 million KRW (up 20.3% from 7,839 million in Q1 2025), consolidated net loss of 120 million KRW (vs net profit of 24 million in prior year period)
Dry eye disease drug GLH8NDE: Phase 3 topline results announced in April 2025, marketing authorization application submitted to MFDS in November 2025; domestic market size estimated at 390 billion KRW
Consolidated total borrowings 20,305 million KRW, net debt 17,285 million KRW, cash and cash equivalents 3,020 million KRW, gearing ratio 46.6%
Consolidated R&D expenses totaled 509 million KRW (5.4% of sales), including 387 million in operating R&D and 122 million capitalized development costs
No shareholder return measures (dividends, share buybacks, cancellations) were implemented
Consolidated trade receivables 7,399 million KRW, allowance for doubtful accounts 116 million KRW (1.54%), inventories 10,638 million KRW

ADVERTISEMENT (250px+)